Atorvastatin Use Associated With Acute Pancreatitis
A Case-Control Study in Taiwan

Shih-Wei Lai, MD, Cheng-Li Lin, MS, and Kuan-Fu Liao, MD, MS

Abstract: Few data are present in the literature on the relationship between atorvastatin use and acute pancreatitis. The aim of this study was to explore this issue in Taiwan.

Using representative claims data established from the Taiwan National Health Insurance Program, this case–control study consisted of 5810 cases aged 20 to 84 years with a first-time diagnosis of acute pancreatitis during the period 1998 to 2011 and 5733 randomly selected controls without acute pancreatitis. Both cases and controls were matched by sex, age, comorbidities, and index year of diagnosing acute pancreatitis. Subjects who at least received 1 prescription for other statins or nonstatin lipid-lowering drugs were excluded from the study. If subjects never had 1 prescription for atorvastatin, they were defined as never use of atorvastatin. Current use of atorvastatin was defined as subjects whose last remaining 1 tablet of atorvastatin was noted ≤7 days before the date of diagnosing acute pancreatitis. Late use of atorvastatin was defined as subjects whose last remaining 1 tablet of atorvastatin was noted >7 days before the date of diagnosing acute pancreatitis. The odds ratio with 95% confidence interval of acute pancreatitis associated with atorvastatin use was calculated by using the logistic regression analysis.

The logistic regression analysis revealed that the odds ratio of acute pancreatitis was 1.67 for subjects with current use of atorvastatin (95% confidence interval 1.18, 2.38), when compared with subjects with never use of atorvastatin. The odds ratio decreased to 1.15 for those with late use of atorvastatin (95% confidence interval 0.87, 1.52), but without statistical significance.

Current use of atorvastatin is associated with the diagnosis of acute pancreatitis. Clinically, clinicians should consider the possibility of atorvastatin-associated acute pancreatitis when patients present with a diagnosis of acute pancreatitis without a definite etiology but are taking atorvastatin.

INTRODUCTION

A torvastatin is one of HMG-CoA reductase inhibitors, which are often known as statins and are commonly used to treat hypercholesterolemia with considerable effectiveness. Generally speaking, atorvastatin is a relatively safe and well-tolerated statin with rare adverse effects including mild gastrointestinal disturbances, elevated serum transaminase levels, and muscle-related disorders. However, few cases have been reported that atorvastatin could be associated with acute pancreatitis as monotherapy or in combination with other offending drugs. The U.S. Food and Drug Administration has also reported that since 1997 to 2013, 1183 persons (0.91%) had pancreatitis among 129,845 persons reporting to have side effects when taking atorvastatin.

Acute pancreatitis is known as an acute inflammatory condition of the pancreas with the potential for severe morbidity and mortality. The etiologies of acute pancreatitis have been extensively explored worldwide, such as alcohol consumption, biliary stones, hypertriglyceridemia, and diabetes mellitus. In addition, many drugs have been found to be associated with acute pancreatitis. Cases of drug-related acute pancreatitis are estimated to account for about 2% of acute pancreatitis cases.

Any adverse drug event needs further investigation based on a systematic analysis before a cause–effect relationship can be established. Given the increased use of atorvastatin and the aforementioned case reports and the U.S. Food and Drug Administration report, we make a plausible hypothesis that there could be a relationship between atorvastatin use and acute pancreatitis. To our knowledge, the clinical relationship between atorvastatin use and acute pancreatitis using a population-based study has not yet been explored. If the relationship really exists, atorvastatin-associated acute pancreatitis should be taken in consideration when patients presenting with a diagnosis of acute pancreatitis without a definite etiology and concomitantly taking atorvastatin. Therefore, we used the claims data of the Taiwan National Health Insurance Program to explore the relationship between atorvastatin use only and acute pancreatitis.

METHODS

Data Source

The National Health Insurance Program was organized by the Taiwan government in 1995 as a nationwide, single-payer health insurance program. This program has enrolled about 99% of the entire population of 23 million people living in Taiwan. The National Health Insurance Research Database contained historical reimbursement claim data from the National Health Insurance Program. The details of the insurance program were well described in previous high-quality studies. Shortly speaking, The National Health Insurance Research Database

OBSERVATIONAL STUDY
was maintained and managed by National Health Research Institute. Before releasing claim data for research, the National Health Research Institute created a scrambled and anonymous identification number to link each insured individual reimbursement claim data, including sex, birth date, and medical services record. The National Health Research Institute released the Longitudinal Health Insurance Database, which is a subset of the National Health Insurance Research Database. The Longitudinal Health Insurance Database contains all ambulatory and inpatient claims data on 1 million beneficiaries who were randomly sampled from the 2000 registry for beneficiaries of the National Health Insurance Research Database. For Personal Information Protection Act, all researchers must sign an agreement for no intention of attempting to obtain the privacy of patients. The study was approved by the institutional review board of China Medical University and Hospital in Taiwan (CMUH-104-REC2–115). Diseases were coded according to the International Classification of Diseases 9th Revision Clinical Modification (ICD-9 code), 2001 edition.

**Study Design and Identification of Cases and Controls**

This case–control study used data extracted from the Longitudinal Health Insurance Database. Subjects aged 20 to 84 years with a first-time diagnosis of acute pancreatitis during the period 1998 to 2011 were identified as cases (ICD-9 code 577.0). The index date for each case was defined as the date of diagnosing acute pancreatitis. Controls also aged 20 to 84 years were randomly selected from those without acute pancreatitis. Both cases and controls were matched by sex, age (every 5-year span), comorbidities, and index year of diagnosing acute pancreatitis. To increase unbiased results, subjects with chronic pancreatitis (ICD-9 code 577.1) or pancreatic cancer (ICD-9 code 157) before the date of diagnosing acute pancreatitis were excluded from the study. To focus on the relationship between atorvastatin use only and acute pancreatitis, subjects who at least received 1 prescription for other statins or nonstatin lipid-lowering drugs were excluded from the study.

**Comorbidities Potentially Related to Acute Pancreatitis**

Comorbidities before the date of diagnosing acute pancreatitis potentially related to acute pancreatitis were included as follows: alcohol-related disease (ICD-9 codes 291, 303, 305.00, 305.01, 305.02, 305.03, 571.0–571.3, 790.3, and V11.3), biliary stone (ICD-9 code 574), cardiovascular disease including coronary artery disease, heart failure, cerebrovascular disease and peripheral atherosclerosis (ICD-9 codes 410–414, 428, 430–438, and 440–448), chronic kidney disease (ICD-9 codes 585–586 and 588.8–588.9), chronic obstructive pulmonary disease (ICD-9 codes 491, 492, 493, and 496), hepatitis B (ICD-9 codes V02.61, 070.20, 070.22, 070.30, and 070.32), hepatitis C (ICD-9 codes V02.62, 070.41, 070.44, 070.51, and 070.54), hyperparathyroidism (ICD-9 code 252.0), and hypertriglyceridemia (ICD-9 codes 272.1, 272.2, and 272.4). Based on ICD-9 codes, the diagnosis accuracy of comorbidities included has been well assessed in previous studies.19–23

**Definition of Atorvastatin Use**

The mean elimination half-life of atorvastatin ranges from 11 to 24 h in healthy people.24,25 Therefore, we used the period of 7 days as a cut-off point. If subjects never had 1 prescription for atorvastatin, they were defined as never use of atorvastatin. According to the prescription history, we can estimate the last remaining 1 tablet for atorvastatin. We adapted the definition of medication use from previous studies.26,27 Current use of atorvastatin was defined as subjects whose last remaining 1 tablet of atorvastatin was noted ≤7 days before the date of diagnosing acute pancreatitis or those still having atorvastatin tablets at the date of diagnosing acute pancreatitis. Late use of atorvastatin was defined as subjects whose last remaining 1 tablet of atorvastatin was noted >7 days before the date of diagnosing acute pancreatitis.

**Statistical Analysis**

Cases and controls were compared for demographic status, atorvastatin use, and comorbidities using the chi-square test and the Fisher exact test for categorical variables and the t test for continuous variables. Initially, all variables were included in the univariable unconditional logistic regression model to calculate the crude odds ratio (OR) and 95% confidence interval (CI) for the association between variables and acute pancreatitis. Then, significant variables found in the univariable analysis were further included in the multivariable unconditional logistic regression model. We used the SAS software for all data analysis (version 9.2 for Windows; SAS Institute Inc, Cary, NC). A P value <0.05 was considered statistically significant.

**RESULTS**

**Descriptive Characteristics of the Study Population**

Distributions of demographic status, atorvastatin use, and comorbidities between cases of acute pancreatitis and controls during the period 1998 to 2011 are shown in Table 1. We identified 5810 cases of acute pancreatitis and 5733 controls with similar distributions of sex, age, and comorbidities. The cases were more likely to have higher proportions of current use of atorvastatin and late use of atorvastatin than the controls (1.45% vs 0.87% for current use, and 1.89% vs 1.66% for late use, respectively, \( P = 0.01 \)).

**Atorvastatin Use and Risk of Acute Pancreatitis**

The univariable unconditional logistic regression model revealed that the odds ratio of acute pancreatitis was 1.67 for subjects with current use of atorvastatin (95% confidence interval 1.18, 2.38), when compared with subjects with never use of atorvastatin. The odds ratio decreased to 1.15 for those with late use of atorvastatin (95% confidence interval 0.87, 1.52), but without statistical significance (Table 2). Because no other variable was significantly related to acute pancreatitis in the univariable analysis, we did not perform the multivariable unconditional logistic regression model.

**DISCUSSION**

As well known, the etiologies of acute pancreatitis have been extensively explored worldwide, such as alcohol consumption, biliary stones, hypertriglyceridemia, and diabetes mellitus.11–13 In order to diminish the confounding effects from these well-known risk factors, both cases and controls were well matched with comorbidities studied during the selection process of samples. Therefore, there was a similar distribution of comorbidities (Table 1). We could explore the relationship between atorvastatin use and acute pancreatitis without confounding. After matched with sex, age, and comorbidities in...
cases and controls, we observed a modestly increased odds ratio of acute pancreatitis in patients with current use of atorvastatin as compared to those with never use of atorvastatin (odds ratio 1.67, 95% confidence interval 1.18, 2.38), but patients with late use of atorvastatin did not have a significant association. This means that currently taking atorvastatin might be associated with acute pancreatitis, independent of other comorbidities. Those who did not currently take atorvastatin might not have this association. Atorvastatin is a cholesterol-lowering agent, not treatment for gastro-intestinal diseases. Before conducting this study, no study revealed whether patients with acute pancreatitis might have higher proportion of taking atorvastatin. In this study, we observed that the cases of acute pancreatitis were more likely to have higher proportions of current use of atorvastatin and late use of atorvastatin than the controls (1.45% vs 0.87% for current use, and 1.89% vs 1.66% for late use, respectively, Table 1).

Although the exact mechanism of atorvastatin-associated acute pancreatitis cannot be fully clarified in this observational study, the direct toxic effect or idiosyncratic reaction of atorvastatin on the pancreas can partially explain this relationship because a dose–response effect was not found (data not shown). That is, patients with atorvastatin-associated acute pancreatitis may be allergic or hypersensitive to this drug. Another possible mechanism can be partially explained by

### TABLE 1. Descriptive Characteristics of Cases With Acute Pancreatitis and Control Subjects in Taiwan During the Period 1998 to 2011

| Variables                                      | Controls N = 5733 | Cases N = 5810 | P^  
|------------------------------------------------|-------------------|----------------|------
| Sex                                            |                   |                | 0.98 |
| Female                                         | 1846 (32.2)       | 1872 (32.2)    |      |
| Male                                           | 3887 (67.8)       | 3938 (67.8)    |      |
| Age group, y                                   |                   |                | 0.99 |
| 20–39                                          | 1964 (34.3)       | 1984 (34.2)    |      |
| 40–64                                          | 2612 (45.6)       | 2652 (45.7)    |      |
| 65–84                                          | 1157 (20.2)       | 1174 (20.2)    |      |
| Age (year), mean (standard deviation)^\(\d\)  | 49.0 (16.1)       | 49.2 (15.9)    | 0.42 |
| Atorvastatin                                   |                   |                | 0.01 |
| Never use                                      | 5588 (97.47)      | 5616 (96.66)   |      |
| Current use                                    | 50 (0.87)         | 84 (1.45)      |      |
| Late use                                       | 95 (1.66)         | 110 (1.89)     |      |
| Comorbidities before index date                |                   |                |      |
| Alcohol-related disease                        | 756 (13.2)        | 797 (13.7)     | 0.40 |
| Biliary stone                                  | 1158 (20.2)       | 1203 (20.7)    | 0.50 |
| Cardiovascular disease                         | 1119 (19.5)       | 1159 (20.0)    | 0.56 |
| Chronic kidney disease                         | 155 (2.70)        | 177 (3.05)     | 0.27 |
| Chronic obstructive pulmonary disease          | 779 (13.6)        | 804 (13.8)     | 0.70 |
| Diabetes mellitus                              | 726 (12.7)        | 755 (13.0)     | 0.59 |
| Hepatitis B                                    | 231 (4.03)        | 259 (4.46)     | 0.25 |
| Hepatitis C                                    | 114 (1.99)        | 147 (2.53)     | 0.05 |
| Hyperparathyroidism\(^\d\)                     | 10 (0.17)         | 11 (0.19)      | 0.85 |
| Hypertriglyceridemia                           | 427 (7.45)        | 462 (7.95)     | 0.31 |

Data are presented as the number of subjects in each group, with percentages given in parentheses, or mean with standard deviation given in parentheses.

^\(\d\) Chi-square test.

\(^\d\) Fisher-exact test.

\(^z\) t test comparing subjects with and without acute pancreatitis.

### TABLE 2. Odds Ratio and 95% Confidence Interval of Acute Pancreatitis Associated With Atorvastatin Use and Other Comorbidities in Taiwan During the Period 1998 to 2011

| Variables                                      | OR (95% CI)  
|------------------------------------------------|-------------|
| Sex (male vs female)                           | 1.00 (0.92, 1.08)  
| Age (per 1 year)                               | 1.00 (0.99, 1.00)  
| Atorvastatin (never use as a reference)        | 1.67 (1.18, 2.38)  
| Current use                                    | 1.15 (0.87, 1.52)  
| Late use                                       | 1.15 (0.87, 1.52)  
| Comorbidities before index date (yes vs no)    |             |
| Alcohol-related disease                        | 1.03 (0.94, 1.13)  
| Biliary stone                                  | 1.03 (0.94, 1.13)  
| Cardiovascular disease                         | 1.02 (0.92, 1.14)  
| Chronic kidney disease                         | 1.13 (0.91, 1.41)  
| Chronic obstructive pulmonary disease          | 1.02 (0.92, 1.14)  
| Diabetes mellitus                              | 1.03 (0.92, 1.15)  
| Hepatitis B                                    | 1.11 (0.93, 1.33)  
| Hepatitis C                                    | 1.28 (0.99, 1.64)  
| Hyperparathyroidism\(^\d\)                     | 1.09 (0.46, 2.56)  
| Hypertriglyceridemia                           | 1.07 (0.94, 1.23)  

CI = confidence interval, OR = odds ratio.
drug-drug interactions between atorvastatin and other concomitantly used drugs, which are mainly mediated by cytochrome P450 3A4 isoenzyme inhibition.\textsuperscript{4,2,23,24} That is, the potentially toxic effect of atorvastatin on the pancreas is expanded by concomitantly used drugs, which might inhibit cytochrome P450 3A4 isoenzyme.

To date, few cases have been reported that atorvastatin could be associated with acute pancreatitis as monotherapy or in combination with other offending drugs,\textsuperscript{4,9} but no case received the re-challenge test to confirm a cause–effect relationship. Similarly, the report of adverse drug reaction regarding atorvastatin-related pancreatitis published by the US Food and Drug Administration did not confirm a cause–effect relationship.\textsuperscript{10,11} In our study, in order to reduce the biased results, subjects who at least received 1 prescription for other statins or nonstatin lipid-lowering drugs were excluded from the study. Therefore, this study was to focus on atorvastatin use only and association of acute pancreatitis. In spite of a case–control study, our results were less confounded by other lipid-lowering drugs or comorbidities. To date, no other pharmacoepidemiological study focusing on atorvastatin use only and association of acute pancreatitis is available to be compared with. Further prospective trials are required to elucidate the precise relationship between atorvastatin use and acute pancreatitis.

Some important limitations should be considered in this study. First, theoretically, we should compare the group with atorvastatin use only and the group without using any drug. It is relatively difficult to design a case–control study using such an inclusion criteria. Second, many drugs have occasional case reports of acute pancreatitis occurring in association. Theoretically, all prescribed medications including atorvastatin should be corrected for analysis. In fact, it is relatively difficult to include all prescribed medications for analysis. Third, not knowing whether patients did take it or not, we used atorvastatin prescriptions for instead. Fourth, the etiologies of acute pancreatitis were not recorded due to the inherent limitation of this database. It was very hard to estimate how many patients with idiopathic acute pancreatitis could be substantially related to atorvastatin use but not detected clinically. Fifth, whether the association between atorvastatin use and acute pancreatitis could be a class effect with HMG-CoA reductase inhibitors cannot be determined in this study focusing only on atorvastatin, unless other statins and their possible association with acute pancreatitis are clarified. Sixth, a cause–effect relationship between atorvastatin use and acute pancreatitis cannot be completely established by our observational study. More prospective studies are needed to establish whether atorvastatin use is a risk factor for acute pancreatitis.

Some strengths of this study should be considered. This topic is of great importance and intriguing, due to the worldwide use of this medication. We utilized the national healthcare database of Taiwan, which encompasses 99\% of the whole population living in Taiwan,\textsuperscript{15} to perform a well-matched case-control study to explore the association of atorvastatin use with acute pancreatitis. The statistical methodology is excellent and the conclusions appear straightforward. It provides the update information for further research.

We conclude that current use of atorvastatin is associated with the diagnosis of acute pancreatitis, independent of other comorbidities. Clinically, clinicians should consider the possibility of atorvastatin-associated acute pancreatitis when patients present with a diagnosis of acute pancreatitis without a definite etiology but are taking atorvastatin.

ACKNOWLEDGEMENTS

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019). This funding agency did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

1. Malinowski JM. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health Syst Pharm. 1998;55:2253–2267.

2. Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther. 2001;15:211–218.

3. Athyros VG, Tzimalos K, Karagiannis A, et al. Atorvastatin: safety and tolerability. Expert Opin Drug Saf. 2010;9:667–674.

4. Belaïche G, Ley G, Slama JL. Acute pancreatitis associated with atorvastatin therapy. Gastroenterol Clin Biol. 2000;24:471–472.

5. Mikliádous G, Anthopoulos A, Elissaf M. Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy. JOP. 2003;4:20–21.

6. Singh S, Nautiyal A, Dolan JG. Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect? JOP. 2004;5:502–504.

7. Kanbay M, Sekuk H, Yilmaz U, et al. Acute pancreatitis associated with combined lisinopril and atorvastatin therapy. Dig Dis. 2005;23:92–94.

8. Prajapati S, Shah S, Desai C, et al. Atorvastatin-induced pancreatitis. Indian J Pharmacol. 2010;42:324–325.

9. Deshpande PR, Khera K, Thunga G, et al. Atorvastatin-induced acute pancreatitis. J Pharmacol Pharmacother. 2011;2:40–42.

10. eHealthMe study from FDA and social media reports. Review: could atorvastatin cause pancreatitis? http://www.ehealthme.com/print/ds15955104 [cited in 2015 January 1].

11. Gan SI, Edwards AL, Symonds CJ, et al. Hypertriglyceridaemia-induced pancreatitis: a case-based review. World J Gastroenterol. 2006;12:7197–7202.

12. Lai SW, Muo CH, Liao KF, et al. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol. 2011;106:1697–1704.

13. Vidasdottir H, Moller PH, Thorarinssdottir H, et al. Acute pancreatitis: a prospective study on incidence, etiology, and outcome. Eur J Gastroenterol Hepatol. 2013;25:1068–1075.

14. Wilmink T, Frick TW. Drug-induced pancreatitis. Drug Saf. 1996;14:406–423.

15. Ksidzyna D. Drug-induced acute pancreatitis related to medications commonly used in gastroenterology. Eur J Intern Med. 2011;22:20–25.

16. National Health Insurance Research Database. Taiwan. http://nhrd.nhi.gov.tw/en/index.html [cited in 2015 December 1, English version].

17. Lai SW, Liao KF, Liao CC, et al. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore). 2010;89:295–299.

18. Hung SC, Liao KF, Lai SW, et al. Risk factors associated with symptomatic cholelithiasis in Taiwan: a population-based study. BMC Gastroenterol. 2011;11:111.

19. Liao KF, Lai SW, Li CI, et al. Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol. 2012;27:709–713.
20. Lai SW, Liao KF, Mao CH, et al. No association between statin use and pancreatic cancer risk in Taiwan. *Kuwait Med J.* 2013;45:251–252.

21. Lai SW, Liao KF, Lin CL, et al. Pyogenic liver abscess correlates with increased risk of acute pancreatitis: a population-based cohort study. *J Epidemiol.* 2015;25:246–253.

22. Lai SW, Lai HC, Lin CL, et al. Chronic osteomyelitis correlates with increased risk of acute pancreatitis in a case-control study in Taiwan. *Eur J Intern Med.* 2015;26:429–432.

23. Liao K-F, Lin C-L, Lai S-W, et al. Parkinson’s disease and risk of pancreatic cancer: a population-based case-control study in Taiwan. *Neurology Asia.* 2015;20:251–255.

24. Cilla DD Jr, Whitfield LR, Gibson DM, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. *Clin Pharmacol Ther.* 1996;60:687–695.

25. Poli A. Atorvastatin: pharmacological characteristics and lipid-lowering effects. *Drugs.* 2007;67(suppl 1):3–15.

26. Liao KF, Lin CL, Lai SW, et al. Zolpidem use associated with increased risk of pyogenic liver abscess: a case-control study in Taiwan. *Medicine (Baltimore).* 2015;94:e1302.

27. Liao KF, Lin CL, Lai SW, et al. Sitagliptin use and risk of acute pancreatitis in type 2 diabetes mellitus: a population-based case-control study in Taiwan. *Eur J Intern Med.* 2016;27:76–79.

28. Lennernas H. Clinical pharmacokinetics of atorvastatin. *Clin Pharmacokinet.* 2003;42:1141–1160.